Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belatacept - Bristol-Myers Squibb

Next Previous
X
Search
Drug Profile

Belatacept - Bristol-Myers Squibb

Alternative Names: BMS-224818; LEA 29Y; Nulojix

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Emory University; National Heart, Lung and Blood Institute
  • Class Antirheumatics; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action CD80 antigen inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase II Lung transplant rejection
  • Discontinued Liver transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 03 Mar 2023 No development reported - Phase-III for Renal transplant rejection (In adolescents, In children, Treatment-experienced) in France (IV)
  • 22 Feb 2023 No development reported - Phase-III for Renal transplant rejection (In the elderly, Prevention, Treatment-experienced, In adults) in Switzerland, Sweden, Netherlands, Greece, Germany, France, Austria (IV) (Bristol-Myers Squibb pipeline, February 2023)
  • 31 Aug 2022 Bristol-Myers Squibb in collaboration with Washington University School of Medicine and National Heart, Lung, and Blood Institute completes a phase II trial in Lung transplant rejection (Combination therapy, Prevention) in USA (IV) (NCT03388008)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top